Date: 2014-09-25
Type of information: Capital increase
Company: Santen Holdings (The Netherlands)
Investors: Santen Pharmaceutical (Japan)
Amount: € 42 million (Approximately ¥6 billion)
Funding type: capital increase
Planned used: The purpose of this increase of capital of its subsidiary in Europe, Santen Holdings EU B.V., is to establish subsidiaries in those countries which Santen expects to expand business in relation to the assets acquisition transaction entered with Merck, which was signed on May 13th, 2014, within Europe and its surrounding areas, including Switzerland, Italy, Spain, the United Kingdom and Turkey.
Others: * On September 25, 2014, Santen Pharmaceutical Co announced that it was resolved at the Board of Director meeting held on September 25, 2014 to increase capital for Santen Holdings EU B.V., a consolidated wholly owned holding company in Europe.
Santen has set forth the goal of \"Becoming a specialized pharmaceutical company with a global presence\" as its long-term strategic vision for 2020. In the Fiscal 2014–2017 Medium-Term Management Plan, Santen proposed a strategic objective of strengthening business development in Europe.
Therapeutic area: Ophtalmological diseases
